Healthpeak Properties, Inc. (DOC)
| Market Cap | 14.26B +11.6% |
| Revenue (ttm) | 2.95B +5.5% |
| Net Income | 242.74M +47.5% |
| EPS | 0.34 +46.8% |
| Shares Out | 702.53M |
| PE Ratio | 59.51 |
| Forward PE | 95.22 |
| Dividend | $1.22 (6.01%) |
| Ex-Dividend Date | Sep 14, 2026 |
| Volume | 1,763,980 |
| Open | 20.48 |
| Previous Close | 20.51 |
| Day's Range | 20.20 - 20.57 |
| 52-Week Range | 15.70 - 22.95 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 23.05 (+13.55%) |
| Earnings Date | Oct 22, 2026 |
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery. Healthpeak Properties, Inc. is based in Denver, Colorado. Healthpeak Properties, Inc. was incorporated in 1985 in Maryland.
Financial Performance
In 2025, Healthpeak Properties's revenue was $2.82 billion, an increase of 4.52% compared to the previous year's $2.70 billion. Earnings were $70.51 million, a decrease of -70.91%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for DOC stock is "Buy." The 12-month stock price target is $23.05, which is an increase of 13.55% from the latest price.
News
Healthpeak Properties, Inc. (NYSE: DOC) President and CEO Scott Brinker Interviewed by Advisor Access
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Healthpeak Properties, Inc. (NYSE: DOC) is a fully integrated real estate investment trust (REIT) and S&P 500 company.
Healthpeak Properties price target raised to $24 from $23 at Barclays
Barclays raised the firm’s price target on Healthpeak Properties (DOC) to $24 from $23 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the healthcare…
Healthpeak Properties price target raised to $25 from $24 at BofA
BofA analyst Farrell Granath raised the firm’s price target on Healthpeak Properties (DOC) to $25 from $24 and keeps a Buy rating on the shares. The firm updated its price…
Healthpeak Properties price target raised to $24 from $21 at Baird
Baird raised the firm’s price target on Healthpeak Properties (DOC) to $24 from $21 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results…
Healthpeak Properties price target raised to $22 from $20 at Citi
Citi raised the firm’s price target on Healthpeak Properties (DOC) to $22 from $20 and keeps a Neutral rating on the shares.
Healthpeak Properties price target raised to $23 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Richard Anderson raised the firm’s price target on Healthpeak Properties (DOC) to $23 from $20 and keeps a Neutral rating on the shares.
Healthpeak Properties Earnings Call Transcript: Q2 2026
Q2 2026 saw strong leasing and occupancy gains across outpatient, lab, and senior housing, with FFO adjusted guidance raised and leverage below 5x. Major capital recycling and strategic partnerships, including a $1B Brookfield JV, strengthened the balance sheet.
Healthpeak Properties Earnings release: Q2 2026
Healthpeak Properties released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Healthpeak Properties Quarterly report: Q2 2026
Healthpeak Properties has published its Q2 2026 quarterly earnings report on August 5, 2026.
Healthpeak Properties reports Q2 adjusted FFO per share 46c, consensus 44c
Reports revenue $771.6M, consensus $725.16M.
Healthpeak Properties raises FY26 adjusted FFO per share view $1.73-$1.77
Previous view $1.71-$1.75, consensus $1.75. Sees total same-store cash NOI 0%-1.5%.
Healthpeak Properties Reports Second Quarter 2026 Results and Increases Full Year 2026 Earnings Guidance
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results ...
Best 3 REITs to own for reliable passive income in 2026
As central bank policy stabilizes and real estate valuations recalibrate, income-focused investors are increasingly looking toward real estate investment trusts (REITs) to secure durable cash flows. H...
Healthpeak Properties, Brookfield Asset Management form $2.1B joint venture
Healthpeak Properties (DOC) and Brookfield Asset Management (BAM) announced the formation of a long-term strategic capital partnership through a joint venture involving a portfolio of outpatient medic...
Healthpeak Properties and Brookfield Form a $2.1 Billion Strategic Joint Venture
DENVER & NEW YORK--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak") and Brookfield Asset Management (NYSE: BAM, TSX: BAM) (“Brookfield”), today announced the formation of a long...
Top 10 Dividend Stocks to Buy in 2026
In this bonus episode of The Morning Filter podcast, co-hosts Dave Sekera and Susan Dziubinski talk dividend stock investing. They unpack the performance of dividend stocks during the first half of 20...
Healthpeak Properties price target raised to $22 from $20 at Wells Fargo
Wells Fargo raised the firm’s price target on Healthpeak Properties (DOC) to $22 from $20 and keeps an Equal Weight rating on the shares as part of an earnings preview…
Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Third Quarter of 2026
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on July 9...
Healthpeak Properties price target raised to $21.50 from $19 at UBS
UBS raised the firm’s price target on Healthpeak Properties (DOC) to $21.50 from $19 and keeps a Neutral rating on the shares.
Healthpeak Properties initiated with an Equal Weight at Barclays
Barclays initiated coverage of Healthpeak Properties (DOC) with an Equal Weight rating and $23 price target While initiating coverage of six healthcare REITs, the analyst tells investors that healthca...
Healthpeak Properties price target raised to $24 from $21 at Mizuho
Mizuho analyst Vikram Malhotra raised the firm’s price target on Healthpeak Properties (DOC) to $24 from $21 and keeps an Outperform rating on the shares.
Healthpeak Properties price target raised to $21 from $18 at JPMorgan
JPMorgan raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $18 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Healthpeak Properties Publishes Its 15th Annual Corporate Impact Report
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. ("Healthpeak") (NYSE: DOC) announced today the release of its 15th annual 2025 Corporate Impact Report (the "Report"). The Report highlights Health...
Healthpeak Properties resumed with a Market Perform at Raymond James
Raymond James resumed coverage of Healthpeak Properties (DOC) with a Market Perform rating and no price target The firm sees flattish earnings growth into the second half of 2027 for…